Please login to the form below

Ionis

This page shows the latest Ionis news and features for those working in and with pharma, biotech and healthcare.

Akcea steals march on Alnylam with NICE approval

NICE has announced today that it has been able to change its mind on Tegsedi and issued a positive recommendation after Akcea (a subsidiary of Ionis) offered an improved commercial agreement.

Latest news

UniQure gets speedy US review for Huntington’s gene therapy

The biotech’s one-shot gene therapy approach is up against other huntingtin-lowering therapies, including antisense-based therapies from Roche/Ionis and Takeda/Wave Life Sciences that attempt to bind ... Roche and Ionis’ RG6042 (IONIS-HTTRX) is
Novartis in-licenses Akcea’s novel cardiovascular therapy

The drug, now named TQJ230, is based on the RNA-targeting platform developed by Akcea and its parent company Ionis, and targets Lp(a), a lipoprotein which carries raised cardiovascular risk
UniQure cleared to start Huntington gene therapy trial

Meanwhile, Roche and Ionis have positive phase 1/2 results with an antisense drug called RG6042 that blocks the huntingtin gene from making the protein and recently started a pivotal trial
NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Tegsedi from Akcea (a subsidiary of Ionis).
Biogen picks up another drug from wide-ranging Ionis alliance

" />. Aims to follow success of Spinraza. Biogen’s longstanding collaboration with Ionis has already resulted in one marketed drug – Spinraza – and it’s now taken up rights to another for amyotrophic ... Under the terms of the deal, Ionis

More from news
Approximately 14 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in
Deal Watch October 2018

Joint development using SQZ’s cell therapy. platform. $1.375B. Option. Ionis. RNA‐targeted therapeutics for complement mediated. ... RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

While Onpattro has outshone Ionis’ product in safety and efficacy, analysts see Onpattro’s lack of cardiovascular claims in its US label as a weak point. ... England’s NICE is just beginning its review of Onpattro (in tandem with a review of
The European Medicines Agency: PRIME’d for access?

Since March 2018 Roche, with Ionis, have added another PRIME drug to their portfolio. ... RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease.
Deal Watch February 2017

Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... As part of the agreement Ionis will also expand the collaboration

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Editor – Medical Education Agency – Bucks: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Director – Healthcare PR: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Director, Medical Education: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...